Moderna PPandE Turnover Trend from 2010 to 2022

MRNA
 Stock
  

USD 175.55  4.37  2.55%   

Moderna PPandE Turnover is increasing over the years with slightly volatile fluctuation. Ongoing PPandE Turnover is projected to grow to 25.92 this year. From 2010 to 2022 Moderna PPandE Turnover quarterly data regression line had arithmetic mean of 5.32 and r-squared of  0.38. Moderna Consolidated Income is projected to increase significantly based on the last few years of reporting. The past year's Consolidated Income was at 12.2 Billion. The current year Earning Before Interest and Taxes EBIT is expected to grow to about 14.3 B, whereas Preferred Dividends Income Statement Impact is forecasted to decline to about 19.1 M.
  
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna main balance sheet or income statement drivers, such as Direct Expenses of 2.8 B, Consolidated Income of 13.2 B or Cost of Revenue of 2.1 B, as well as many exotic indicators such as Long Term Debt to Equity of 0.0349, Calculated Tax Rate of 7.29 or PPandE Turnover of 25.92. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules. It can also supplement Moderna's financial leverage analysis and stock options assessment as well as various Moderna Technical models . Additionally, see the analysis of Moderna Correlation against competitors.

Moderna PPandE Turnover Breakdown

Showing smoothed PPandE Turnover of Moderna with missing and latest data points interpolated. Moderna's PPandE Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moderna's overall financial position and show how it may be relating to other accounts over time.
PPandE Turnover10 Years Trend
Increasing
Slightly volatile
   PPandE Turnover   
Share
       Timeline  

Moderna PPandE Turnover Regression Statistics

Arithmetic Mean 5.32
Geometric Mean 2.35
Coefficient Of Variation 164.54
Mean Deviation 6.05
Median 1.87
Standard Deviation 8.75
Sample Variance 76.64
Range 25.63
R-Value 0.62
Mean Square Error 51.51
R-Squared 0.38
Significance 0.023904
Slope 1.39
Total Sum of Squares 919.64

Moderna PPandE Turnover History

2018 0.77
2019 0.29
2020 3.22
2021 24.02
2022 25.92

About Moderna Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moderna income statement, its balance sheet, and the statement of cash flows. Moderna investors use historical funamental indicators, such as Moderna's PPandE Turnover, to determine how well the company is positioned to perform in the future. Although Moderna investors may use each financial statement separately, they are all related. The changes in Moderna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moderna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moderna Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
PPandE Turnover 24.02  25.92 
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3200 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moderna Correlation against competitors. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.19
Market Capitalization
67 B
Quarterly Revenue Growth YOY
0.091
Return On Assets
0.46
Return On Equity
1.14
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.